INTRODUCTION 2 8
Very few studies have been done "in vivo" since 1975 when Solter and Knowles coined the 2 9 term of "immunosurgery". These authors were able to ablate the trophectoderm cells in mouse 3 0 embryos by using antibody and complement. In 2007 Chen and Melton by using antibodies 1 0 5 performed next experiments focused on dilutions of 1/00 and 1/40 for antiSSEA1 and BRS, Evaluation of cellular lysis with trypan blue after challenges with antiSSEA1 and BRS. In Embryonic development and number of PGCs in embryos treated with deposition of 1 1 5 antiSSEA1 and baby rabbit serum to the dorsal side of epiblast. Two times of embryo 1 1 6 development were evaluated, "early development" 24 hours after the application of the 1 1 7 treatment (Fig 1b C and D) and "late development" 3-day. The evaluation of embryonic 1 1 8 development revealed that the treatments and transfer manipulations did not affect neither 1 1 9 embryo "early development" (67-100%) nor "late development" (56-90%) in any of the 1 2 0 treated groups (AntiSSEA1 10/C+, 100/C+ and 1000/C+ groups) compared with control 1 2 1 groups (AntiSSEA1-/C-and AntiSSEA1-/C+), Table 1 . The mean survival days was 4.7, as 1 2 2 expected in normal embryo development following Perry´s system II (Fig 2a) , with no 1 2 3 significant differences between treatments. However, the number of PGCs detected was 1 2 4 decreased in treated (4, 2.7 and 4 PGCs in AntiSSEA1 10/C+, 100/C+ and 1000/C+ groups, 1 2 5 respectively) compared with control embryos (50 and 45 PGCs in AntiSSEA1-/C-and
AntiSSEA1-/C+) (Fig 2b) . A total of 2,400 tissue sections were immunostained and Ex-ovo dose-response study with deposition of antiSSEA1 and baby rabbit serum to the dorsal 1 3 1 side of epiblast. In all control embryos the PGCs counts were in the order of hundreds, while 1 3 2 the percentage of embryos with scarce or without PGCs were increasing with 1/10 and 1/100 1 3 3 concentration of antiSSEA1. The dose-response study evaluated "in toto" revealed that 1 3 4 antiSSEA1 100/C+ 1/40 was the most effective treatment destroying PGCs, because none of 1 3 5
PGCs were seen in any embryo receiving this treatment ( Table 2 and Fig 2c) . Embryos treated with injections into the subgerminal space. The evaluation of embryonic survival revealed that the injected treatments and transfer manipulations did not affect neither 1 4 0 embryo "early development" (67-100%) nor "late development" (50-75%) in any of the 1 4 1 treated groups (AntiSSEA1 100/C+100, 100/C+1000 and /C+10000 groups) compared with 1 4 2 controls (AntiSSEA1-/C-and AntiSSEA1-/C+1000), Table 3 . The mean survival for injected 1 4 3 embryos (4.4 days) was not different from top-dressed ones (4.7 days; Table 3 and Fig 3a) . Unexpectedly, when antibody and complement were injected together in a single injection, 1 5 2 only half of the embryos reached "early development" and none "late development" (Table 3 1 5 3
and Fig 3a) . Immunocytochemistry and histological studies 1 5 8
Immunohistochemistry in tissue sections. In top-dressed and injected embryos, a total of 6,900 1 5 9 tissue sections were immunostained and the number of PGCs counted (Fig 4) .
The data "number of PGCs" have been already presented above (Fig 2b and 3b ). Immunohistochemistry "in toto". In order to stain PGCs the embryos needed a strong hours at room temperature, respectively). In control embryos the presence of hundreds of gonads but some are in their way migrating from the aorta, only PGCs were marked. In some embryos of the antiSSEA1-/C+ group the immunocytohistology showed hundreds of 1 6 9 labelled cells in their gonads but the labeling was not as strong as in the antiSSEA1-/C-group 1 7 0 ( Fig 5D E) . The confirmation of the PGCs presence was made with a histological Alcian 1 7 1
Blue-PAS staining ( Fig 5F) . In contrast, none of the four treated embryos showed any PGCs Our results demonstrated that immune-mediated ablation is an effective method for 1 7 9
decimating the internal population of PGCs when preparing recipient chick embryos for germ instrumentation is needed (stereomicroscope or micro injector) and it is the most gentle on the dilutions, respectively. These doses are coincident with our results obtained in the "in vitro" 1 8 8 competition studies with SBRCs. We must emphasize that the duration of embryonic 1 8 9 development and the organic structures were normal. There was a concern that this form of 1 9 0 administration could be insufficient, as the molecules of antiSSEA1 and complement must studies in using this route, since PGCs are concentrated on the hypoblast at stage X. This was the reason why direct treatment injection on the subgerminal space, that is,
immediately below the hypoblast, was also assayed. We expected this route would be more 1 9 7 effective on PGCs but also more damaging on the embryo because of repeated puncture of the injected antibody is not washed away after a short reaction time as when top-dressed. In both strategies, the natural Ig and innate complement system present in BRS could be Pathway activation (C 1q ). Gerhart´s results and the fact that in stage X embryos, neither 2 1 0 complement enzymes nor IgM are present, support this mechanism. AntiSSEA1 has been 2 1 1 antiVASA would be available.
We assayed a third administration strategy, joint injection of antiSSEA1 plus BRS into the 2 1 6
subgerminal space, in case the double injection proved too detrimental to embryo viability. cytolysis over certain cell populations, the "modus operandi" is: the cells are first exposed to binding lectins (bind to mannose) and ficolins (bind to GlcNAc or fucose). The latter need enzymes (C 4 and C 2 ), which in turn, will destroy indiscriminately blastodermal cells. However, obviously the question of why antibody-complement together strongly increased 2 4 0 cytolitic efects needs to be further investigated. antibody-complement previously to its local application could be very useful to treat large 2 5 0 established tumours from which available antibodies exist and also to potentiate the antibody 2 5 1 efficiency.
5 2
On the other hand, the lack of cytolytic response in our control, demonstrates that complement 2 5 3 alone, even when directly injected into the subgerminal space at the highest concentration 2 5 4 (C+1/10 dilution), is not cytotoxic for the developing stage X embryo: it failed to reduce the 2 5 5 endogenous PGCs population and it did not affect embryo viability at all. Therefore, two protocols successfully produced lysis of the primordial germ cells by specific 2 5 7 cell labelling with antibody followed by heterologous serum with innate complement system of producing an almost complete ablation of the germline cells in chicken embryos with a 2 6 1 high efficiency without damaging other embryonic structures at stage X embryos. welfare and sanitary EU standards. Veronal buffer containing Ca 2+ and Mg 2+ , SRBCs). All reactives were generously supplied by settle down in round-bottom ELISA plates.
7 8
A total of 32 blastoderms were isolated from embryonated eggs at oviposition and 2 7 9 disaggregated with repeated pipetting for three competitive studies. First, the blastoderm cell 2 8 0 suspensions of ten stage X embryos (300 μl approx 10 7 cells/ml) were incubated in assay denotes excess complement activity in the mix. The degree of haemolysis was measured as 2 9 0 the absorbance of the supernatants at 405nm. Saturation curves revealed that CH 50 was 2 9 1 reached after adding BRS between a range of 1/10 -1/100 dilutions. Next, a total of 26 entire blastoderms were isolated for the evaluation of cell viability with cell culture medium M199 in four experiments following previously described culture (1/100 and 1/1000) incubated during 45 minutes at 37ºC and then to BRS (1/50). After incubation for an additional hour at 37ºC, the evaluation of cell destruction was made adding 2 9 8 4% trypan blue (4μl). Control blastoderms were incubated with only M199 or BRS+M199. Ex-ovo treatments applied to stage X embryos and incubated in surrogated egg shells 3 0 0
following Perry´s system II 3 0 1
Deposition of antiSSEA1 and baby rabbit serum to the dorsal side of epiblast. Embryonated dishes to expose and manipulate the embryos following Gerhart's procedure (Gerhart et al. were free from albumen, 100 μl of antiSSEA1 (1/10, 1/100 and 1/1000) were pipetted on top blastoderm was covered with parafilm and incubated for another hour in the same conditions. 3 1 5
After washing the BRS, the contents of eggs were transferred to surrogate egg shells 3 1 6
following Perry´s system II (Perry, 1988) . A total of 50 embryos were evaluated and 3 1 7
histologically studied from three different experiments with at least 4 embryos per treatment antiSSEA1 -/C+). 37 °C saturated with moisture for 1 hour. Later, BSR was injected at different dilutions 3 2 5
(1/100, 1/1000 and 1/10000). After the last injection the contents of eggs were transferred to with at least 4 embryos per treatment group (antiSSEA1 -/C-, antiSSEA1 100/C100,
antiSSEA1 100/C+1000, antiSSEA1 100/C+10000 and antiSSEA1 -/C+1000). In order to rule Treatment with a single injection into the subgerminal space. Six embryos were injected into 3 3 3 the subgerminal space as indicated above, except that antiSSEA1 and BRS were jointly 3 3 4 applied in a single injection (antiSSEA1 10/C+10). after the application of the treatment, germinal disc showed normal growth and no yolk 3 3 8
leaking was seen. On third day "late development" was recorded as normal when the vessels 3 3 9
were formed and the heart was beating. Embryos were incubated at least until 5-6 day in an (Sigma B0529, for monoclonal first antibody) followed by AP conjugated streptavidin (Sigma 3 5 5 E2636). Fast Red was used as substrate chromogen. To avoid interference by the potential 3 5 6 immunosurgery PGCs 2 3 endogenous activity of AP, the tissues were treated with 0.02 M levamisole or heat inactivated 3 5 7 at 70 ºC for 30 minutes.
3 5 8
Dose-response study. In the dose-response study the number of PGCs was evaluated "in toto" antimouse alexa 488 (24 hours at room temperature, Invitrogen) and antiSSEA1 as primary PGCs, specially all those treated only with complement, the gonads were stained with Alcian 3 7 3
Blue and PAS (Merk Germany 1.016460001) following the manufacturer´s instructions. 
